✦ LIBER ✦

Who should receive the liver allograft: The transplant center or the recipient?

✍ Scribed by Klintmalm, Goran B.

Publisher: Wiley (John Wiley & Sons)
Year: 1995
Tongue: English
Weight: 400 KB
Volume: 1
Category: Article
ISSN: 1074-3022
DOI: 10.1002/lt.500010112

No coin nor oath required. For personal study only.

✦ Synopsis

Welchel JD. For the UNOS Ad Hoc Allocation Committee. Background: problems and concerns in equitable organ allocation. Appendix D to the UNOS Statement of Principles and Objectives of Equitable Organ Allocation. Richmond: UNOS, 1994:26-43. Welchel JD. For the UNOS Ad Hoc Allocation Committee. Background: problems, and concerns in equitable organ allocation. Appendix D to the UNOS Statement of Principles and Objectives of Equitable Organ Allocation.

📜 SIMILAR VOLUMES

Drivers of the cost of liver transplanta

Drivers of the cost of liver transplantation: Is it the donor, the recipient, or the center?

✍ Robert S. Brown Jr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Mortality risk versus other endpoints: W

Mortality risk versus other endpoints: Who should come first on the liver transplant waiting list?

✍ Richard B. Freeman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

Outcomes in liver transplant recipients

Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade

✍ Guy W. Neff; Christopher B. O'Brien; Jose Nery; Norah Shire; Marzia Montalbano; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

Hepatitis B virus (HBV) recurrence following liver transplantation (LTx) has been controllable primarily with the use of hepatitis B immune globulin (HBIg) and lamivudine (LAM). However, HBV resistance to LAM and/or HBIg has become an increasing problem prompting the use of newer antiviral agents. T

A prospective cross-over study comparing

A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection

✍ Amany Zekry; Margret Gleeson; Seren Guney; Geoffrey W. McCaughan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

It has been suggested that Mycophenolate Mofetil (MMF) may have an antiviral effect in patients with recurrent HCV infection post-liver transplantation. We conducted a prospective cross-over study in liver transplant recipients with recurrent chronic HCV infection to examine whether substitution of

Which is the best surgery for budd-chiar

Which is the best surgery for budd-chiari syndrome: Venous decompression or liver transplantation? a single-center experience with 50 patients

✍ Burckhardt Ringe; Hauke Lang; Karl-Jürgen Oldhafer; Michael Gebel; Peer Flemming 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 836 KB

The optimal treatment of Budd-Chiari syndrome (BCS) remains an open question. It is still a matter of controversial discussion whether venous decompression or liver transplantation is superior. To elucidate the role and prognosis of both surgical options in our own experience, a consecutive series o

Long-term renal function in liver transp

Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study

✍ Svetlana Karie-Guigues; Nicolas Janus; Faouzi Saliba; Jerome Dumortier; Christop 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

The prevalence of renal insufficiency before and at 1, 12, and 60 months after liver transplantation (LTx; primary endpoint) and the changes in the glomerular filtration rate (GFR) at same time points according to the immunosuppressive regimen (coprimary endpoint) were investigated. The primary outc